Overview

Erythropoietin to Prevent Unnecessary Transfusions In Patients With Cyanotic CHD - A Prospective Control Trial

Status:
Active, not recruiting

Trial end date:
2021-03-01

Target enrollment:

Participant gender:

Summary

Cyanotic congenital cardiac patients require higher hemoglobin concentrations (red blood cell levels) for optimal oxygen delivery to the body. Prophylactic erythropoietin (EPO) and iron can prevent and/or decrease the amount of blood transfusions needed in this population. We seek to investigate if EPO and iron make a clinically significant difference in the number of transfusions given to these patients and the morbidity associated with it.

Phase:

Phase 2

Details

Lead Sponsor:

University of California, San Diego

Treatments:

Epoetin Alfa
Iron